SCHEMBL2255277

SCHEMBL2255277

CCCCCC(CC)CC(=O)OC

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.47
CYP3A4 P08684 2/20 0.47
ATM Q13315 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
ZDHHC7 Q9NXF8 1/20 0.46
BIRC2 Q13490 1/20 0.45
CA2 P00918 3/20 0.44
CA1 P00915 1/20 0.44
RECQL P46063 2/20 0.43
MEN1 O00255 1/20 0.43
HPGD P15428 1/20 0.43
KMT2A Q03164 1/20 0.43
HSD17B10 Q99714 1/20 0.43
PRSS1 P07477 1/20 0.43
PRSS2 P07478 1/20 0.43
PRSS3 P35030 1/20 0.43
LMNA P02545 2/20 0.42
ALDH1A1 P00352 2/20 0.42
USP2 O75604 1/20 0.42
GPR84 Q9NQS5 4/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27860764 0.98 ZDHHC7 (0.49) TSHRCYP3A4ATMTDP1ZDHHC7
SCHEMBL30311170 0.98 ZDHHC7 (0.49) TSHRCYP3A4ATMTDP1ZDHHC7
SCHEMBL10441271 0.98 ZDHHC7 (0.49) TSHRCYP3A4ATMTDP1ZDHHC7
SCHEMBL14022813 0.94 CYP3A4 (0.53) TSHRCYP3A4ATMTDP1BIRC2
SCHEMBL15027359 0.92 ZDHHC7 (0.48) TSHRCYP3A4ATMTDP1ZDHHC7
SCHEMBL5075427 0.90 ZDHHC7 (0.52) ZDHHC7BIRC2RECQLMEN1HPGD
SCHEMBL19645435 0.90 ZDHHC7 (0.52) ZDHHC7BIRC2RECQLMEN1HPGD
SCHEMBL22590010 0.90 ZDHHC7 (0.52) ZDHHC7BIRC2RECQLMEN1HPGD
SCHEMBL5074118 0.90 ZDHHC7 (0.52) ZDHHC7BIRC2RECQLMEN1HPGD
SCHEMBL5079165 0.90 ZDHHC7 (0.52) ZDHHC7BIRC2RECQLMEN1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7994152-B2 Method of treating a cancer by administering A 2′,5′-oligoadenylate analog SANKYO COMPANY, LIMITED (JP) 2011-08-09 US disclosed
US-20100035976-A1 Method of treating a tumor or a viral disease by administering a 2' , 5' -oligoadenylate analog SANKYO COMPANY, LIMITED (JP) 2010-02-11 US disclosed
US-7651999-B2 phosphorothioate modification containg oligonadenylates useful as antiviral, anticarcinogenic and antitumor agent; stable and have superior activity for treating lung cancer SANKYO COMPANY, LIMITED (JP) 2010-01-26 US disclosed
US-20050261235-A1 2' ,5' -Oligoadenylate analogs SANKYO COMPANY, LIMITED (JP) 2005-11-24 US disclosed
EP-1568704-A1 NOVEL 2' ,5' -OLIGOADENYLIC ACID ANALOGUES Sankyo Company, Limited (JP) 2005-08-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050261235-A1 2' ,5' -Oligoadenylate analogs NSUN2, RNGTT, NSUN3 TSHR 1870/4885CYP3A4 3167/4885ATM 1895/4885
US-20100035976-A1 Method of treating a tumor or a viral disease by administering a 2' , 5' -oligoadenylate analog ADAR, NSUN2, ADORA3 TSHR 1214/4885CYP3A4 3565/4885ATM 893/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.